Labcorp Holdings (LH) Cash & Equivalents (2009 - 2026)

Labcorp Holdings has disclosed Cash & Equivalents across 18 years of filings, most recently posting $141.8 million for Q2 2026.

• In Q2 2026, Cash & Equivalents fell 78.09% year-over-year to $141.8 million; the TTM figure through Jun 2026 stood at $141.8 million (down 78.09% YoY), while the FY2025 annual figure was $532.3 million, down 64.95% from the prior year.
• Cash & Equivalents came in at $141.8 million for Q2 2026 at Labcorp Holdings, down from $981.1 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $1.9 billion in Q2 2023 to a low of $99.3 million in Q1 2024.
• Average Cash & Equivalents over 5 years is $738.5 million, with a median of $567.4 million recorded in 2023.
• Year-over-year, Cash & Equivalents sank 86.27% in 2024 and soared 272.0% in 2025.
• Over 5 years, Cash & Equivalents stood at $320.6 million in 2022, then soared by 67.44% to $536.8 million in 2023, then surged by 182.92% to $1.5 billion in 2024, then plunged by 64.95% to $532.3 million in 2025, then plunged by 73.36% to $141.8 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $141.8 million in Q2 2026, $981.1 million in Q1 2026, and $532.3 million in Q4 2025.